华东医药: 浙江天册律师事务所关于华东医药股份有限公司2025年第一次临时股东大会的法律意见书

Group 1 - The legal opinion letter is issued by Zhejiang Tiance Law Firm regarding the first extraordinary general meeting of shareholders of East China Pharmaceutical Co., Ltd. in 2025 [1][2] - The meeting was proposed and convened by the board of directors, with the notice published on July 1, 2025, in designated media and on the Shenzhen Stock Exchange website [2][3] - The meeting utilized a combination of on-site and online voting methods, with specific voting times outlined for both platforms [3] Group 2 - The attendees of the meeting included all registered ordinary shareholders of the Shenzhen branch, who could appoint proxies to attend and vote [4] - A total of 799 shareholders participated, representing 1,153,814,388 shares, which accounted for 65.7790% of the total shares with voting rights [4] - The qualifications of the attendees were verified and deemed compliant with relevant laws and regulations [4] Group 3 - The voting procedures followed the legal and regulatory requirements, with a named voting method employed for the agenda items [5] - All proposed resolutions were approved by the shareholders during the meeting, confirming the validity of the voting process [5] - The conclusion of the legal opinion affirmed that the meeting's procedures, qualifications of attendees, and voting results were all in accordance with the law and the company's articles of association [5]